MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy (Q39880558)

15 September 2017

title

MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy (English)

1 reference

15 September 2017

1 reference

1 reference

1 reference

Todd Boren

1 reference

15 September 2017

Yin Xiong

1 reference

15 September 2017

Ardeshir Hakam

1 reference

15 September 2017

Robert Wenham

1 reference

15 September 2017

Sachin Apte

1 reference

15 September 2017

Gina Chan

1 reference

15 September 2017

Siddharth G Kamath

1 reference

15 September 2017

Dung-Tsa Chen

1 reference

15 September 2017

Holly Dressman

1 reference

15 September 2017

Johnathan M Lancaster

1 reference

15 September 2017

language of work or name

English

0 references

publication date

23 February 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

113

1 reference

15 September 2017

1 reference

15 September 2017

page(s)

249-255

1 reference

Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum–taxane chemotherapy

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II study of gemcitabine in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNAs: genomics, biogenesis, mechanism, and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Post-transcriptional gene silencing by siRNAs and miRNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Silence from within: endogenous siRNAs and miRNAs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNA expression profiles classify human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

c-Myc-regulated microRNAs modulate E2F1 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNA signatures in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

A microRNA expression signature of human solid tumors defines cancer gene targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNAs modulate the chemosensitivity of tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNA expression profiles for the NCI-60 cancer cell panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Acetone extract of Bupleurum scorzonerifolium inhibits proliferation of A549 human lung cancer cells via inducing apoptosis and suppressing telomerase activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

miRBase: microRNA sequences, targets and gene nomenclature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Genomic signatures to guide the use of chemotherapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Breast cancer metastasis: a microRNA story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Micro-RNA profiling in kidney and bladder cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNA expression profiles in serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

miR-21-mediated tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Overview of microarray analysis of gene expression and its applications to cervical cancer investigation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2009.01.014

1 reference

15 September 2017

1 reference